A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia

Published:2007-06-21 Issue:9 Volume:21 Page:1964-1970
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Mesa R A,Camoriano J K,Geyer S M,Wu W,Kaufmann S H,Rivera C E,Erlichman C,Wright J,Pardanani A,Lasho T,Finke C,Li C Y,Tefferi A

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2404816.pdf

Reference37 articles.

1. 1. Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 2007, (in press)

2. 2. [Eh pub ahead of print, 6 January 2007].

3. Tefferi A . Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 342: 1255–1265.

4. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A . Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005; 105: 973–977.

5. Devine SM, Hoffman R, Verma A, Shah R, Bradlow BA, Stock W et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002; 99: 2255–2258.

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging treatments for classical myeloproliferative neoplasms;Blood;2017-02-09

2. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase;Leukemia Research;2015-09

3. Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis;Cochrane Database of Systematic Reviews;2015-04-10

4. Orphan drugs for myelofibrosis;Expert Opinion on Orphan Drugs;2014-02-13

5. Targeting Mutant KRAS for Anticancer Therapeutics: A Review of Novel Small Molecule Modulators;Journal of Medicinal Chemistry;2013-04-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3